Using synergistic effects in targeting angiogenesis: combination therapy for corneal neovascularization

References

• You IC, Im SK, Lee SH, Yoon KC. Photodynamic therapy with verteporfin combined with subconjunctival injection of bevacizumab for corneal neovascularization. Cornea30(1), 30–33 (2011).
   PubMed Web of Science ®Google Scholar
• Burger PC, Chandler DB, Klintworth GK. Experimental corneal neovascularization: biomicroscopic, angiographic, and morphologic correlation. Cornea4(1), 35–41 (1985).
   PubMedGoogle Scholar
• Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr. Opin. Ophthalmol.12(4), 242–249 (2001).
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med.1(1), 27–31 (1995).
   PubMed Web of Science ®Google Scholar
• Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans. Am. Ophthalmol. Soc.104, 264–302 (2006).
   PubMedGoogle Scholar
• Ellenberg D, Azar DT, Hallak JA et al. Novel aspects of corneal angiogenic and lymphangiogenic privilege. Prog. Retin. Eye Res.29(3), 208–248 (2010).
   PubMed Web of Science ®Google Scholar
• Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv. Ophthalmol.43(3), 245–269 (1998).
   PubMed Web of Science ®Google Scholar
• Sugisaki K, Usui T, Nishiyama N et al. Photodynamic therapy for corneal neovascularization using polymeric micelles encapsulating dendrimer porphyrins. Invest. Ophthalmol. Vis. Sci.49(3), 894–899 (2008).
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Hasan T, Gragoudas E, Michaud N, Flotte TJ, Birngruber R. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology101(12), 1953–1961 (1994).
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv. Ophthalmol.45(3), 195–214 (2000).
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Hasan T, Schomacker K, Flotte T, Birngruber R. In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization. Lasers Surg. Med.17(2), 178–188 (1995).
   PubMed Web of Science ®Google Scholar
• No authors listed. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials – TAP report. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) study group. Arch. Ophthalmol.117(10), 1329–1345 (1999).
   PubMed Web of Science ®Google Scholar
• Barbazetto IA, Lee TC, Abramson DH. Treatment of conjunctival squamous cell carcinoma with photodynamic therapy. Am. J. Ophthalmol.138(2), 183–189 (2004).
   PubMed Web of Science ®Google Scholar
• Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea27(2), 142–147 (2008).
   PubMed Web of Science ®Google Scholar
• Lange N, Ballini JP, Wagnieres G, van den Bergh H. A new drug-screening procedure for photosensitizing agents used in photodynamic therapy for CNV. Invest. Ophthalmol. Vis. Sci.42, 38–46 (2001).
   PubMed Web of Science ®Google Scholar
• Debefve E, Pegaz B, Ballini JP, van den Bergh H. Combination therapy using verteporfin and ranibizumab; optimizing the timing in the CAM model. Photochem. Photobiol.85(6), 1400–1408 (2009).
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest. Ophthalmol. Vis. Sci.44(10), 4473–4480 (2003).
   PubMed Web of Science ®Google Scholar
• Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch. Ophthalmol.119(2), 198–207 (2001).
   PubMed Web of Science ®Google Scholar
• Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology110(8), 1517–1525 (2003).
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Michels S, Augustin A. Perspectives on verteporfin therapy combined with intravitreal corticosteroids. Arch. Ophthalmol.124(4), 561–563 (2006).
   PubMedGoogle Scholar
• Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog. Retin. Eye Res.27(4), 331–371 (2008).
   PubMed Web of Science ®Google Scholar
• Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr. Eye Res.33(1), 23–28 (2008).
   PubMed Web of Science ®Google Scholar
• Schlotzer-Schrehardt U, Viestenz A, Naumann GO, Laqua H, Michels S, Schmidt-Erfurth U. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch. Clin. Exp. Ophthalmol.240(9), 748–757 (2002).
   PubMed Web of Science ®Google Scholar
• Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology115(6), e33–e38 (2008).
   Web of Science ®Google Scholar
• Hashemian MN, Z-Mehrjardi H, Moghimi S. Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats. Ophthalmic. Res.46(1), 50–54 (2011).
   PubMed Web of Science ®Google Scholar
• Bock F, Onderka J, Rummelt C et al. Safety profile of topical VEGF neutralization at the cornea. Invest. Ophthalmol. Vis. Sci.50(5), 2095–2102 (2009).
   PubMed Web of Science ®Google Scholar
• Kim EC, Lee WS, Kim MS. The inhibitory effects of bevacizumab eye drops on NGF expression and corneal wound healing in rats. Invest. Ophthalmol. Vis. Sci.51(9), 4569–4573 (2010).
   PubMed Web of Science ®Google Scholar
• Nomoto H, Shiraga F, Kuno N et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest. Ophthalmol. Vis. Sci.50(10), 4807–4813 (2009).
   PubMed Web of Science ®Google Scholar
• Cho M, Barbazetto IA, Freund KB. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am. J. Ophthalmol.148(1), 70–78.e71 (2009).
   PubMed Web of Science ®Google Scholar
• Yoon KC, You IC, Kang IS et al. Photodynamic therapy with verteporfin for corneal neovascularization. Am. J. Ophthalmol.144(3), 390–395 (2007).
   PubMed Web of Science ®Google Scholar
• Yoon KC, Im SK, Park HY. Recurrent herpes simplex keratitis after verteporfin photodynamic therapy for corneal neovascularization. Cornea29(4), 465–467 (2010).
   PubMed Web of Science ®Google Scholar